ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Antibiotic maker Tetraphase goes cheap

by Ryan Cross
March 21, 2020 | APPEARED IN VOLUME 98, ISSUE 11

 

AcelRx Pharmaceuticals, an opioid-drug maker, is buying Tetraphase Pharmaceuticals for a mere $14.4 million. Tetraphase sells Xerava, a tetracycline antibiotic administered via injection to treat multidrug-resistant infections. When Xerava was approved in August 2018, the firm’s stock rose to more than $70 a share; earlier this month it was trading for less than $1. Tetraphase has amassed losses of $600 million and sold only $3.6 million worth of Xerava in 2019.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment